Latest Articles
Acrivon to present ACR-368 endometrial cancer data at ESGO congress - Investing.com Nigeria
Acrivon to present ACR-368 endometrial cancer data at ESGO congress Investing.com Nigeria
Published: Jan. 24, 2026, 5:45 a.m.
Acrivon to present ACR-368 endometrial cancer data at ESGO congress By Investing.com - Investing.com India
Acrivon to present ACR-368 endometrial cancer data at ESGO congress By Investing.com Investing.com India
Published: Jan. 24, 2026, 4:02 a.m.
Acrivon to present ACR-368 endometrial cancer data at ESGO congress - Investing.com Canada
Acrivon to present ACR-368 endometrial cancer data at ESGO congress Investing.com Canada
Published: Jan. 23, 2026, 10:24 p.m.
Acrivon to present ACR-368 endometrial cancer data at ESGO congress - Investing.com Australia
Acrivon to present ACR-368 endometrial cancer data at ESGO congress Investing.com Australia
Published: Jan. 23, 2026, 3:48 p.m.
Acrivon to present ACR-368 endometrial cancer data at ESGO congress - Investing.com
Acrivon to present ACR-368 endometrial cancer data at ESGO congress Investing.com
Published: Jan. 23, 2026, 2:07 p.m.
Acrivon to present ACR-368 endometrial cancer data at ESGO congress - Investing.com UK
Acrivon to present ACR-368 endometrial cancer data at ESGO congress Investing.com UK
Published: Jan. 23, 2026, 1:18 p.m.
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer - Targeted Oncology
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer Targeted Oncology
Published: Jan. 22, 2026, 4:02 p.m.
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer - targetedonc.com
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer targetedonc.com
Published: Jan. 22, 2026, 4:02 p.m.
Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery - Cureus
Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery Cureus
Published: Jan. 21, 2026, 1:51 p.m.
Endometrial Cancer Market Poised to Grow from USD 16.89 Billion in 2024 to USD 32.77 Billion by 2035 - openPR.com
Endometrial Cancer Market Poised to Grow from USD 16.89 Billion in 2024 to USD 32.77 Billion by 2035 openPR.com
Published: Jan. 21, 2026, 1:15 p.m.
Link copied to clipboard!